Rykaczewska-Czerwińska M, Konopińska D, Plech A
Department of Pharmacology Medical Faculty in Zabrze of the Medical University of Silesia, H. Jordana 38, PL 41-808, Zabrze, Poland.
Comp Biochem Physiol C Toxicol Pharmacol. 2001 Nov;130(3):271-9. doi: 10.1016/s1532-0456(01)00230-7.
The antinociceptive effect of intracerebroventricular injections of [2-8]-leucopyrokinin (LPK), a truncated leucopyrokinin analogue, was determined in rats, by means of a tail immersion test. We found a significant antinociceptive effect of three i.c.v. doses of [2-8]-LPK: 1, 5 and 10 nmol. Pre-treating animals with naloxone hydrochloride (1 mg/kg i.p.) completely blocked the effect of two high doses of [2-8]-LPK. To determine the sub-types of opioid receptors involved in [2-8]-leucopyrokinin-induced analgesia we injected specific blockers of mu-, delta- and kappa-receptors namely, beta-funaltrexamine hydrochloride, naltrindole hydrochloride and nor-binaltorphimine dihydrochloride, respectively, prior to [2-8]-leucopyrokinin at equimolar doses. We conclude that the antinociceptive effect of [2-8]-leucopyrokinin is mediated mainly by central mu- and delta-opioid receptors.